Buchu (Agathosma betulina)

Agathosma betulina (syn. Barosma betulina)
Evidence Level
Preliminary
4 Clinical Trials
5 Documented Benefits
1/5 Evidence Score

Buchu is the dried leaf of Agathosma betulina, an aromatic shrub from South Africa's Cape region that the Khoisan used long before settlers exported it as a bladder and kidney remedy. It entered European pharmacopoeias in 1826 and stayed in the US National Formulary until 1960, fading once antibiotics arrived. Germany's Commission E later declined to recommend it because its effectiveness had never been documented, and FDA's over-the-counter drug rules list buchu among weight-control and menstrual ingredients lacking adequate evidence. It is still sold as tea, tincture and capsules for urinary support, yet no controlled human trial of oral buchu exists. Its oil also contains pulegone, which damages the liver at high doses and caused liver and bladder tumors in rodents; the related species A. crenulata, also sold as buchu, carries far more.

Studied Dose No human dose tested; used as leaf tea or tincture. Rat buchu-water studies equal about 250 mL/day for a 70 kg adult
Active Compound Volatile oil (isomenthone, limonene, diosphenol, pulegone); flavonoids hesperidin, diosmin, rutin

Benefits

Traditionally used to support urinary tract and bladder comfort

Buchu leaf tea and tincture were a Khoisan and Cape settler remedy for bladder and kidney complaints, and the leaf sat in European and American pharmacopoeias as a urinary herb for more than a century. That is a long history of use, not proof: no controlled human trial has tested oral buchu for urinary health.

Urinary antibacterial activity is weak in lab tests

Buchu's traditional reputation rests on antibacterial action in the urinary tract. In laboratory tests the essential oil showed very low activity against E. coli and Staphylococcus, water and ethanol extracts did not stop E. coli, and only a methanol-dichloromethane lab extract, unlike any tea or tincture, reached moderate activity, at milligram-per-milliliter concentrations. It is not a substitute for an antibiotic.

Kidney support claims have not been tested in people

A nephrology team auditing 184 supplement websites aimed at people with kidney disease found buchu among the ten most promoted plants and concluded these herbs were not adequately studied in humans. Germany's Commission E likewise declined to recommend buchu. People with kidney disease should not use it without their nephrologist.

Smooth muscle relaxing effect in isolated tissue

In guinea-pig intestinal tissue, buchu essential oils caused initial contraction followed by relaxation at high concentrations, apparently through cyclic AMP and, for A. betulina, calcium channel blockade. Early 1800s use of buchu for spasmodic urethral and bladder complaints fits this picture, but the effect has only been shown in an organ bath, never in a human bladder.

Blood sugar and weight findings are limited to rats

Work linked to a company selling a buchu-water extract reported normalized glucose in less severely diabetic rats and lower glucose in the rest and less weight and abdominal fat gain on a high-fat diet. Reviewers noted the extract's composition was undisclosed, no other lab has confirmed the results, and no human trial exists, so these remain animal findings only.

Mechanism of action

1

Diosphenol and sulfur aroma compounds

Buchu leaf oil is dominated by isomenthone, limonene, diosphenol and menthone. Diosphenol and the sulfur compound 8-mercapto-p-menthan-3-one give the blackcurrant note that makes the oil valuable to the flavor industry, which is where most buchu is used today.

2

Pulegone content depends on the species

Pulegone made up about 2 to 8 percent of commercial A. betulina oil in EFSA's batch analyses, while chemotaxonomy studies summarized by reviewers found roughly 32 to 73 percent in A. crenulata oil. Pulegone dissolves poorly in water, so leaf tea carries less than the oil, though not none.

3

Liver toxicity through menthofuran and glutathione loss

Human liver enzymes CYP2E1, CYP1A2 and CYP2C19 convert pulegone to menthofuran, which is oxidized further to reactive products. Glutathione normally neutralizes these; when it runs low, liver injury rises sharply, about tenfold in rats pretreated to deplete glutathione.

4

Citrus-type flavonoids in the leaf

Hesperidin, diosmin and rutin are the leaf's non-volatile marker compounds and help explain antioxidant readings in test-tube assays. In the rat buchu-water studies these flavonoids were present at tiny concentrations, too low to explain the effects reported.

Clinical trials

1
Pharmacology Review of Buchu Research (2022)
PubMed

Narrative review of the historical, chemical, laboratory and animal research on Agathosma betulina and A. crenulata (Brendler T, Abdel-Tawab M 2022, Front Pharmacol 13:813142, PMID 35197854).

No human participants; the reviewers found no clinical trial of oral buchu.

The authors concluded that pharmacological studies to date failed to confirm buchu's traditional use and that any health claim needs randomized, placebo-controlled trials. The only placebo-controlled human study they located tested a topical buchu oil gel on exercise muscle soreness in 30 men and appeared as a research-unit report, so it says nothing about oral use. The first author consults for industry and is part-time employed by the herbal company Traditional Medicinals.

2
Buchu Essential Oils on Gut Tissue and Microbes
PubMed

Laboratory study of A. betulina and A. crenulata essential oils on isolated guinea-pig ileum and on bacterial and yeast cultures (Lis-Balchin M, Hart S, Simpson E 2001, J Pharm Pharmacol 53(4):579-82, PMID 11341377).

No human participants; isolated animal tissue and microbial cultures.

Both oils caused initial contraction and then relaxation of intestinal smooth muscle through a post-synaptic mechanism involving cyclic AMP, with apparent calcium channel blockade for A. betulina. Undiluted oil did not inhibit Enterococcus hirae or Pseudomonas aeruginosa and showed very low activity against E. coli and S. aureus, leading the authors to conclude the oils have little antimicrobial potential.

3
Audit of Kidney Supplement Claims Online
PubMed

Structured evaluation of 184 websites marketing dietary and herbal supplements to people with chronic kidney disease (Vamenta-Morris H, Dreisbach A, Shoemaker-Moyle M, Abdel-Rahman EM 2014, Am J Nephrol 40(5):393-8, PMID 25376340).

Supplement websites scored by two independent reviewers; buchu was one of the ten most common plant ingredients.

28% of sites claimed to slow kidney disease progression, 60% did not advise consulting a doctor, and more than 90% gave no drug interaction, pregnancy or pediatric caution. The authors found that these plants, buchu included, had not been adequately studied in humans, and that the available animal studies for the group showed detrimental effects and potential drug interactions.

4
NTP Two-Year Pulegone Toxicology Study
PubMed

US National Toxicology Program gavage studies of pulegone, the liver-toxic constituent of buchu oil, lasting up to two years (National Toxicology Program 2011, Natl Toxicol Program Tech Rep Ser (563):1-201, PMID 21921962).

F344/N rats and B6C3F1 mice given 18.75 to 150 mg pulegone per kg body weight, 5 days a week, in the two-year arms.

Liver tumors increased in dosed mice, and bladder papilloma or carcinoma increased in high-dose female rats, alongside liver, kidney and nasal damage. In the two-week arm nearly all rats given 300 mg/kg or more died of liver toxicity. These exposures are far above anything a cup of leaf tea supplies, but they are why buchu oil should never be swallowed.

Side effects and drug interactions

Common Potential side effects

No human safety trials exist for oral buchu; tolerability rests on traditional use and flavor-level exposure.
Buchu oil contains pulegone, which injures the liver at high doses; never swallow the essential oil.
A. crenulata carries far more pulegone than A. betulina, and market buchu supplements are often adulterated, so check the species.
Avoid in pregnancy and breastfeeding: high-dose buchu oil affected liver and uterine function in rats, and pulegone-rich pennyroyal has a history of abortifacient use.
The oil is a skin and eye irritant and a skin and respiratory sensitizer.
NIH LiverTox lists no liver injury cases from buchu tea or extracts; stop and seek care if jaundice or dark urine appears.
Not a treatment for a urinary tract infection; burning, fever, back pain or blood in the urine need medical care.

Important Drug interactions

No interaction studies exist for buchu; the points below are precautions based on its constituents and traditional diuretic use.
Lithium: herbs used as diuretics may reduce lithium clearance; avoid unless a prescriber is monitoring levels.
Prescription diuretics: a theoretical additive effect on fluid and electrolyte loss.
Acetaminophen and other liver-toxic drugs: pulegone depletes the same glutathione reserve that protects the liver from acetaminophen.
Alcohol and other CYP2E1 inducers: CYP2E1 converts pulegone to the liver-toxic metabolite menthofuran, so induction could raise exposure.
Antibiotics for a urinary infection: buchu should not replace or delay prescribed treatment.

Frequently asked questions about Buchu (Agathosma betulina)

What is Buchu?

Buchu is the dried leaf of Agathosma betulina, an aromatic shrub from South Africa's Cape region that the Khoisan used long before settlers exported it as a bladder and kidney remedy. It entered European pharmacopoeias in 1826 and stayed in the US National Formulary until 1960, fading once antibiotics arrived.

What is Buchu used for?

Buchu is researched primarily for Kidney/Urinary Tract. Buchu leaf tea and tincture were a Khoisan and Cape settler remedy for bladder and kidney complaints, and the leaf sat in European and American pharmacopoeias as a urinary herb for more than a century.

What is the recommended dosage of Buchu?

The clinically studied dose is No human dose tested; used as leaf tea or tincture. Rat buchu-water studies equal about 250 mL/day for a 70 kg adult Always follow the product label and check with a healthcare provider for personal advice.

Is Buchu safe, and does it have side effects?

For most healthy adults, Buchu is well tolerated at studied doses. Reported effects can include: No human safety trials exist for oral buchu; tolerability rests on traditional use and flavor-level exposure. Buchu oil contains pulegone, which injures the liver at high doses; never swallow the essential oil. It may also interact with some medications. Buchu is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Buchu interact with any medications?

Possible interactions include: No interaction studies exist for buchu; the points below are precautions based on its constituents and traditional diuretic use. Lithium: herbs used as diuretics may reduce lithium clearance; avoid unless a prescriber is monitoring levels. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Buchu?

NutraSmarts rates the evidence for Buchu as Preliminary (1 out of 5). It is backed by 4 clinical trials and 8 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(8 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Brendler T, Abdel-Tawab M. Buchu (Agathosma betulina and A. crenulata): Rightfully Forgotten or Underutilized? Front Pharmacol. 2022;13:813142..PubMedUsed to support: The central source for this page: traces buchu from Khoisan use through pharmacopoeia listings (1826 to the US National Formulary until 1960) and Germany's negative Commission E monograph, finds only weak laboratory antimicrobial activity, describes the company-linked rat buchu-water studies as unconfirmed, reports pulegone at 2.4 to 4.5% in A. betulina oil versus 31.6 to 73.2% in A. crenulata oil, and concludes pharmacological studies failed to confirm the traditional use. The first author discloses industry consulting and part-time employment with Traditional Medicinals.
  2. Moolla A, Viljoen AM. 'Buchu' -Agathosma betulina and Agathosma crenulata (Rutaceae): a review. J Ethnopharmacol. 2008;119(3):413-9..PubMedUsed to support: An academic review from the University of the Witwatersrand assembling buchu's botany, traditional and modern uses, chemistry and pharmacology, noting that the research is limited. Supports the traditional-use history on this page; later reviewers cite it for diosphenol as buchu's distinctive blackcurrant-flavor compound.
  3. Lis-Balchin M, Hart S, Simpson E. Buchu (Agathosma betulina and A. crenulata, Rutaceae) essential oils: their pharmacological action on guinea-pig ileum and antimicrobial activity on microorganisms. J Pharm Pharmacol. 2001;53(4):579-82..PubMedUsed to support: Laboratory study showing the oils relaxed guinea-pig ileum through a cyclic AMP route, with apparent calcium channel blockade for A. betulina, while showing no activity against Enterococcus hirae or Pseudomonas aeruginosa and very low activity against E. coli and S. aureus. No human participants.
  4. Vamenta-Morris H, Dreisbach A, Shoemaker-Moyle M, Abdel-Rahman EM. Internet claims on dietary and herbal supplements in advanced nephropathy: truth or myth. Am J Nephrol. 2014;40(5):393-8..PubMedUsed to support: Audit of 184 websites selling supplements for kidney disease that named buchu among the ten most common plant ingredients and concluded these plants were not adequately studied in humans, with available animal data pointing to harm and drug interactions.
  5. EFSA Panel on Additives, Products or Substances used in Animal Feed (FEEDAP), Bampidis V, Azimonti G, Bastos ML, Christensen H, Fašmon Durjava M, Kouba M, López-Alonso M, López Puente S, Marcon F, Mayo B, Pechová A, Petkova M, Ramos F, Sanz Y, Villa RE, Woutersen R, Brantom P, Chesson A, Westendorf J, Manini P, Pizzo F, Dusemund B. Safety and efficacy of a feed additive consisting of an essential oil from the leaves of Agathosma betulina (P.J. Bergius) Pillans (buchu leaf oil) for use in all animal species (FEFANA asbl). EFSA J. 2022;20(3):e07160..PubMedUsed to support: Regulatory safety opinion on A. betulina leaf oil as a feed flavoring. Its batch analyses found isomenthone, limonene, diosphenol, menthone and 2.13 to 7.81% pulegone, plus menthofuran and methyleugenol; it notes pulegone may not be added as such to food in the EU, summarizes CYP2E1, CYP1A2 and CYP2C19 conversion of pulegone to menthofuran and the role of glutathione, and classes the oil as a skin and eye irritant and sensitizer. It assessed animal feed use, not human supplements.
  6. National Toxicology Program. Toxicology and carcinogenesis studies of pulegone (CAS No. 89-82-7) in F344/N rats and B6C3F1 mice (gavage studies). Natl Toxicol Program Tech Rep Ser. 2011;(563):1-201..PubMedUsed to support: The rodent toxicology behind the pulegone warnings: fatal liver toxicity at 300 mg/kg and above in two-week rat studies, increased liver tumors in dosed mice and bladder papilloma or carcinoma in high-dose female rats over two years. It tested pure pulegone, not buchu leaf.
  7. Anderson IB, Mullen WH, Meeker JE, Khojasteh-BakhtSC, Oishi S, Nelson SD, Blanc PD. Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature. Ann Intern Med. 1996;124(8):726-34..PubMedUsed to support: Human evidence that pulegone-rich oil is dangerous when swallowed: four pennyroyal ingestions, one fatal, with pulegone and menthofuran measured in serum from two of them, and a literature review of 18 earlier cases showing moderate to severe toxicity after at least 10 mL of pennyroyal oil. Also documents pennyroyal's abortifacient use. It concerns pennyroyal, not buchu.
  8. National Institute of Diabetes and Digestive and Kidney Diseases Buchu. LiverTox, National Institute of Diabetes and Digestive and Kidney Diseases. 2023;Bethesda (MD), chapter updated 3 March 2023..PubMedUsed to support: The NIH liver-injury database entry, stating that buchu preparations used as tea and dried extracts have not been linked to serum enzyme elevations or clinically apparent liver injury. A balancing point to the pulegone data, which come from the oil and pure compound.